• Contact info@abtriva.com for inquiries and orders.
  • Chinese (Simplified)

  • English

  • German

  • Korean

  • Spanish

United States (English / $ USD)

Recombinant Human E3 ubiquitin-protein ligase MARCH7 (41340)

ACP10325

Number
Order Exclusive Products Now

Request a Quote
High Purity LevelsPrecision and ReliabilityCustomization Options

Specifications


Cat.No ACP10325 Target Name7-Mar
FormLyophilized powderExpression SystemCustom Production. Please inquire and provide the desire expression system.
Expression Range1-704Protein LengthFull length protein
Purity>85% (SDS-PAGE)Storage Buffer5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, Liquid form: default storage buffer is Tris/PBS-based buffer, pH 8.0.

Immunogen Information


Target SpeciesHumanUniprot IDQ9H992
Background Information
  • Uniprot Id

    Q9H992

  • Target Species

    Human

  • Target Name

    MARCHF7

  • Target Full Name

    E3 ubiquitin-protein ligase MARCHF7

  • Target Function

    E3 ubiquitin-protein ligase which may specifically enhance the E2 activity of HIP2. E3 ubiquitin ligases accept ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester and then directly transfer the ubiquitin to targeted substrates. May be involved in T-cell proliferation by regulating LIF secretion. May play a role in lysosome homeostasis.

  • Target Synonyms

    AXO; AXOT; Axotrophin; E3 ubiquitin-protein ligase MARCH7; MARCH VII ; MARCH-VII; March7; MARH7_HUMAN; Membrane associated RING CH protein VII ; Membrane associated ring finger (C3HC4) 7 E3 ubiquitin protein ligase; membrane associated ring finger C3HC4 7 ; Membrane associated RING finger protein 7; Membrane-associated RING finger protein 7; Membrane-associated RING-CH protein VII; RING finger protein 177; RNF177

Inquire Recombinant Human E3 ubiquitin-protein ligase MARCH7 (41340) Now



AbTriva respects your privacy and protects your personal data in accordance with AbTriva. For more information, please see our data protection statement. *

Notification